CYP (ASX) U.K. approval received for CLI trial

Originally posted by Sector: ↑

Cynata Therapeutics (CYP)Rating: Buy | Risk: High | Price Target: $3.00

UK Regulatory Authority Approves Cynata's Phase 2 Clinical Trial in Critical Limb Ischaemia

EVENT: Further positive developments for CYP and its Cymerus MSC platform continue to support the outlook for both iPSC derived cells and our CYP investment thesis. Shaw and Partners forecasts and recommendation remain unchanged as does our 12 month TP.

HIGHLIGHTS: CYP has announced that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with its Phase 2 clinical trial of the Cymerus™ mesenchymal stem cell (MSC) product CYP-002 in patients with critical limb ischaemia (CLI).

CYP anticipates conducting the clinical trial at multiple centres in the UK and Australia. The trial is expected to start this quarter and involve the recruitment of ~90 patients with advanced CLI, cost are yet to be finalised. The UK is a reputable regulator recognised for good quality trials data outcomes, but it is also a relatively quick path to conducting clinical trials. Ultimately though CYP recognises it will have to go down the regulatory path in other major jurisdictions (e.g. U.S. FDA) if it is to fully access and monetise the CLI treatment opportunity which is forecast to reach a global value of US$5.4 billion by 2025.· The approval also confirms the successful implementation of the Company's strategy to use the positive Phase 1 trial of Cymerus MSCs in graft versus host disease to support direct progression from preclinical to Phase 2 clinical studies for CLI and multiple other indications. We expect this to include the indications CYP has recently generated successful pre-clinical data for.

Essentially the acceptance based on CYP's graft versus host disease phase 1 data fast tracks CYP's other programs which adds further appeal to potential licensing.· CLI is an advanced stage of peripheral artery disease (PAD), which is a narrowing of arteries in the limbs, particularly the legs. The risk of PAD is increased in patients with diabetes, obesity or high blood pressure and also in people who smoke. CLI often results in amputation of the affected limb and is a major risk factor for cardiovascular events such as heart attack.

There are 230,000 addressable events per year.· As previously announced, in a preclinical study in a mouse model of CLI, treatment with Cymerus MSCs led to significantly higher blood flow in the ischaemic limb and protection against muscle damage, fibrosis, and limb loss.

RECOMMENDATION: Since Shaw and Partners initiated coverage on CYP in May 2017 it has licensed its CYP-001 to Fujifilm and appreciated 190%. We expect further out performance as CYP i) moves CYP-001 into GvHD phase 2 trials in 2020, ii) partners a number of other undisclosed indications which it has disclosed it is currently negotiating, and iii) begins the NHMRC funded phase 2 Osteoarthritis clinical trial expected 2019-20. This trial in 448 patients will not only be one of the largest MSC trials ever undertaken, but targets a market opportunity estimated at USD 11.6b by 2025. Our BUY rating is reaffirmed.

Expand

seriously, all it takes to get 2x GA's these days is to cut and paste an analyst report?

yes i'm jealous.. never mind, carry on.

No.	Vol.	Price($)
2	31298	24.5¢

No.

Vol.

Price($)

31298

24.5¢

Price($)	Vol.	No.
25.0¢	39430	1

Price($)

Vol.

No.

25.0¢

39430

No.	Vol.	Price($)
2	31298	0.245
4	112215	0.240
2	119148	0.235
2	15173	0.230
1	20000	0.225

No.

Vol.

Price($)

31298

0.245

112215

0.240

119148

0.235

15173

0.230

20000

0.225

Price($)	Vol.	No.
0.250	39430	1
0.260	25384	1
0.290	1900	1
0.295	183892	1
0.300	85000	2

Price($)

Vol.

No.

0.250

39430

0.260

25384

0.290

1900

0.295

183892

0.300

85000

(20min delay)
Last 25.0¢		Change 0.000(0.00%)		Mkt cap ! $44.90M

Open	High	Low	Value	Volume
25.5¢	26.0¢	24.5¢	$19.72K	78.84K

seriously, all it takes to get 2x GA's these days is to cut and...

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

seriously, all it takes to get 2x GA's these days is to cut and...

Top Stories

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News